nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—Topoisomerase Inhibitors—Etoposide—urinary bladder cancer	0.316	0.43	CiPCiCtD
Topotecan—Topoisomerase Inhibitors—Epirubicin—urinary bladder cancer	0.217	0.296	CiPCiCtD
Topotecan—Topoisomerase Inhibitors—Doxorubicin—urinary bladder cancer	0.201	0.274	CiPCiCtD
Topotecan—ABCB1—Mitomycin—urinary bladder cancer	0.0288	0.169	CbGbCtD
Topotecan—ABCG2—Fluorouracil—urinary bladder cancer	0.0197	0.115	CbGbCtD
Topotecan—ABCG2—Carboplatin—urinary bladder cancer	0.0196	0.115	CbGbCtD
Topotecan—ABCG2—Cisplatin—urinary bladder cancer	0.0167	0.098	CbGbCtD
Topotecan—ABCG2—Etoposide—urinary bladder cancer	0.0164	0.0963	CbGbCtD
Topotecan—CYP3A4—Thiotepa—urinary bladder cancer	0.0131	0.0768	CbGbCtD
Topotecan—ABCG2—Doxorubicin—urinary bladder cancer	0.0112	0.0657	CbGbCtD
Topotecan—ABCG2—Methotrexate—urinary bladder cancer	0.0109	0.0636	CbGbCtD
Topotecan—ABCB1—Gemcitabine—urinary bladder cancer	0.0083	0.0487	CbGbCtD
Topotecan—ABCB1—Cisplatin—urinary bladder cancer	0.00603	0.0354	CbGbCtD
Topotecan—ABCB1—Etoposide—urinary bladder cancer	0.00593	0.0347	CbGbCtD
Topotecan—ABCB1—Doxorubicin—urinary bladder cancer	0.00404	0.0237	CbGbCtD
Topotecan—ABCB1—Methotrexate—urinary bladder cancer	0.00392	0.0229	CbGbCtD
Topotecan—CYP3A4—Etoposide—urinary bladder cancer	0.00355	0.0208	CbGbCtD
Topotecan—TOP1MT—prostate gland—urinary bladder cancer	0.00282	0.178	CbGeAlD
Topotecan—CYP3A4—Doxorubicin—urinary bladder cancer	0.00242	0.0142	CbGbCtD
Topotecan—TOP1MT—female reproductive system—urinary bladder cancer	0.00154	0.097	CbGeAlD
Topotecan—TOP1—prostate gland—urinary bladder cancer	0.00149	0.0937	CbGeAlD
Topotecan—TOP1—seminal vesicle—urinary bladder cancer	0.00126	0.0793	CbGeAlD
Topotecan—TOP1—smooth muscle tissue—urinary bladder cancer	0.00105	0.0664	CbGeAlD
Topotecan—CYP3A4—urine—urinary bladder cancer	0.00102	0.0645	CbGeAlD
Topotecan—TOP1—urethra—urinary bladder cancer	0.000996	0.0627	CbGeAlD
Topotecan—TOP1MT—lymph node—urinary bladder cancer	0.0009	0.0567	CbGeAlD
Topotecan—TOP1—vagina—urinary bladder cancer	0.000734	0.0463	CbGeAlD
Topotecan—TOP1—Caspase Cascade in Apoptosis—BIRC3—urinary bladder cancer	0.000728	0.0657	CbGpPWpGaD
Topotecan—ABCB1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.000651	0.0588	CbGpPWpGaD
Topotecan—ABCG2—prostate gland—urinary bladder cancer	0.000527	0.0332	CbGeAlD
Topotecan—TOP1—lymph node—urinary bladder cancer	0.000475	0.0299	CbGeAlD
Topotecan—TOP1—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000447	0.0403	CbGpPWpGaD
Topotecan—ABCG2—seminal vesicle—urinary bladder cancer	0.000446	0.0281	CbGeAlD
Topotecan—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.000401	0.0362	CbGpPWpGaD
Topotecan—ABCG2—urethra—urinary bladder cancer	0.000353	0.0223	CbGeAlD
Topotecan—TOP1—Caspase Cascade in Apoptosis—FAS—urinary bladder cancer	0.000349	0.0315	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000314	0.0284	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—VHL—urinary bladder cancer	0.000299	0.027	CbGpPWpGaD
Topotecan—ABCG2—vagina—urinary bladder cancer	0.00026	0.0164	CbGeAlD
Topotecan—ABCB1—prostate gland—urinary bladder cancer	0.00026	0.0164	CbGeAlD
Topotecan—ABCG2—Fluoropyrimidine Activity—TYMP—urinary bladder cancer	0.000257	0.0232	CbGpPWpGaD
Topotecan—CYP3A4—renal system—urinary bladder cancer	0.00025	0.0158	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00024	0.0216	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000238	0.0215	CbGpPWpGaD
Topotecan—ABCB1—seminal vesicle—urinary bladder cancer	0.00022	0.0139	CbGeAlD
Topotecan—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00021	0.0189	CbGpPWpGaD
Topotecan—CYP3A4—female reproductive system—urinary bladder cancer	0.000201	0.0126	CbGeAlD
Topotecan—ABCG2—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.000201	0.0181	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000192	0.0173	CbGpPWpGaD
Topotecan—ABCB1—epithelium—urinary bladder cancer	0.000191	0.012	CbGeAlD
Topotecan—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000185	0.0167	CbGpPWpGaD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000184	0.0166	CbGpPWpGaD
Topotecan—ABCB1—renal system—urinary bladder cancer	0.000177	0.0112	CbGeAlD
Topotecan—ABCB1—urethra—urinary bladder cancer	0.000174	0.011	CbGeAlD
Topotecan—ABCG2—lymph node—urinary bladder cancer	0.000168	0.0106	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000152	0.0138	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00015	0.0136	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.00015	0.0135	CbGpPWpGaD
Topotecan—TOP1—Caspase Cascade in Apoptosis—TNF—urinary bladder cancer	0.000148	0.0134	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000144	0.013	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000142	0.0128	CbGpPWpGaD
Topotecan—ABCB1—female reproductive system—urinary bladder cancer	0.000142	0.00895	CbGeAlD
Topotecan—ABCG2—Iron uptake and transport—TFRC—urinary bladder cancer	0.000137	0.0123	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000133	0.012	CbGpPWpGaD
Topotecan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000132	0.0119	CbGpPWpGaD
Topotecan—ABCB1—vagina—urinary bladder cancer	0.000128	0.00809	CbGeAlD
Topotecan—TOP1—Circadian rythm related genes—FAS—urinary bladder cancer	0.000127	0.0115	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000117	0.0106	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000117	0.0105	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000116	0.0105	CbGpPWpGaD
Topotecan—ABCG2—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.000116	0.0105	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000114	0.0102	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000112	0.0101	CbGpPWpGaD
Topotecan—ABCG2—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.000108	0.00974	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000102	0.0092	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000102	0.00919	CbGpPWpGaD
Topotecan—ABCG2—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.000101	0.00915	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000101	0.00908	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	9.7e-05	0.00875	CbGpPWpGaD
Topotecan—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	9.45e-05	0.00853	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	8.54e-05	0.0077	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	8.35e-05	0.00753	CbGpPWpGaD
Topotecan—ABCB1—lymph node—urinary bladder cancer	8.31e-05	0.00524	CbGeAlD
Topotecan—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	8.1e-05	0.00731	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—CREBBP—urinary bladder cancer	7.71e-05	0.00696	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	7.54e-05	0.00681	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	7.3e-05	0.00658	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	7.28e-05	0.00657	CbGpPWpGaD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	7.21e-05	0.00651	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	7.12e-05	0.00642	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—PTEN—urinary bladder cancer	6.99e-05	0.00631	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	6.94e-05	0.00626	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	6.75e-05	0.00609	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—EP300—urinary bladder cancer	6.66e-05	0.00601	CbGpPWpGaD
Topotecan—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	6.21e-05	0.0056	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	6.05e-05	0.00546	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	5.92e-05	0.00534	CbGpPWpGaD
Topotecan—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	5.85e-05	0.000851	CcSEcCtD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	5.84e-05	0.00527	CbGpPWpGaD
Topotecan—Decreased appetite—Cisplatin—urinary bladder cancer	5.84e-05	0.000849	CcSEcCtD
Topotecan—Feeling abnormal—Fluorouracil—urinary bladder cancer	5.84e-05	0.000849	CcSEcCtD
Topotecan—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	5.82e-05	0.00525	CbGpPWpGaD
Topotecan—Pneumonia—Methotrexate—urinary bladder cancer	5.81e-05	0.000846	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	5.81e-05	0.00524	CbGpPWpGaD
Topotecan—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	5.8e-05	0.000844	CcSEcCtD
Topotecan—Infestation—Methotrexate—urinary bladder cancer	5.78e-05	0.000841	CcSEcCtD
Topotecan—Infestation NOS—Methotrexate—urinary bladder cancer	5.78e-05	0.000841	CcSEcCtD
Topotecan—Pancytopenia—Epirubicin—urinary bladder cancer	5.76e-05	0.000838	CcSEcCtD
Topotecan—Pain—Cisplatin—urinary bladder cancer	5.74e-05	0.000836	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	5.73e-05	0.000833	CcSEcCtD
Topotecan—Body temperature increased—Gemcitabine—urinary bladder cancer	5.7e-05	0.000829	CcSEcCtD
Topotecan—Neutropenia—Epirubicin—urinary bladder cancer	5.67e-05	0.000825	CcSEcCtD
Topotecan—Dizziness—Thiotepa—urinary bladder cancer	5.66e-05	0.000824	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	5.63e-05	0.00508	CbGpPWpGaD
Topotecan—Stomatitis—Methotrexate—urinary bladder cancer	5.63e-05	0.00082	CcSEcCtD
Topotecan—Urticaria—Fluorouracil—urinary bladder cancer	5.63e-05	0.000819	CcSEcCtD
Topotecan—Body temperature increased—Fluorouracil—urinary bladder cancer	5.6e-05	0.000815	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	5.59e-05	0.00504	CbGpPWpGaD
Topotecan—Sweating—Methotrexate—urinary bladder cancer	5.54e-05	0.000806	CcSEcCtD
Topotecan—Feeling abnormal—Cisplatin—urinary bladder cancer	5.53e-05	0.000805	CcSEcCtD
Topotecan—Paraesthesia—Etoposide—urinary bladder cancer	5.52e-05	0.000804	CcSEcCtD
Topotecan—Weight increased—Epirubicin—urinary bladder cancer	5.52e-05	0.000803	CcSEcCtD
Topotecan—Dyspnoea—Etoposide—urinary bladder cancer	5.48e-05	0.000798	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—urinary bladder cancer	5.46e-05	0.000795	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—urinary bladder cancer	5.45e-05	0.000793	CcSEcCtD
Topotecan—Vomiting—Thiotepa—urinary bladder cancer	5.45e-05	0.000792	CcSEcCtD
Topotecan—Pneumonia—Epirubicin—urinary bladder cancer	5.44e-05	0.000791	CcSEcCtD
Topotecan—Infestation—Epirubicin—urinary bladder cancer	5.41e-05	0.000787	CcSEcCtD
Topotecan—Infestation NOS—Epirubicin—urinary bladder cancer	5.41e-05	0.000787	CcSEcCtD
Topotecan—Rash—Thiotepa—urinary bladder cancer	5.4e-05	0.000786	CcSEcCtD
Topotecan—Dermatitis—Thiotepa—urinary bladder cancer	5.4e-05	0.000785	CcSEcCtD
Topotecan—Headache—Thiotepa—urinary bladder cancer	5.37e-05	0.000781	CcSEcCtD
Topotecan—Decreased appetite—Etoposide—urinary bladder cancer	5.35e-05	0.000778	CcSEcCtD
Topotecan—Pancytopenia—Doxorubicin—urinary bladder cancer	5.33e-05	0.000775	CcSEcCtD
Topotecan—Gastrointestinal disorder—Etoposide—urinary bladder cancer	5.31e-05	0.000773	CcSEcCtD
Topotecan—Body temperature increased—Cisplatin—urinary bladder cancer	5.31e-05	0.000772	CcSEcCtD
Topotecan—Fatigue—Etoposide—urinary bladder cancer	5.3e-05	0.000772	CcSEcCtD
Topotecan—Neuropathy peripheral—Epirubicin—urinary bladder cancer	5.3e-05	0.000771	CcSEcCtD
Topotecan—Stomatitis—Epirubicin—urinary bladder cancer	5.27e-05	0.000767	CcSEcCtD
Topotecan—Constipation—Etoposide—urinary bladder cancer	5.26e-05	0.000766	CcSEcCtD
Topotecan—Pain—Etoposide—urinary bladder cancer	5.26e-05	0.000766	CcSEcCtD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—EP300—urinary bladder cancer	5.25e-05	0.00474	CbGpPWpGaD
Topotecan—Neutropenia—Doxorubicin—urinary bladder cancer	5.25e-05	0.000763	CcSEcCtD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	5.24e-05	0.00473	CbGpPWpGaD
Topotecan—Hypersensitivity—Fluorouracil—urinary bladder cancer	5.22e-05	0.000759	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—urinary bladder cancer	5.21e-05	0.000759	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—urinary bladder cancer	5.19e-05	0.000755	CcSEcCtD
Topotecan—Sweating—Epirubicin—urinary bladder cancer	5.18e-05	0.000754	CcSEcCtD
Topotecan—Asthenia—Gemcitabine—urinary bladder cancer	5.17e-05	0.000752	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—urinary bladder cancer	5.15e-05	0.000749	CcSEcCtD
Topotecan—Hepatobiliary disease—Epirubicin—urinary bladder cancer	5.11e-05	0.000744	CcSEcCtD
Topotecan—Weight increased—Doxorubicin—urinary bladder cancer	5.11e-05	0.000743	CcSEcCtD
Topotecan—Epistaxis—Epirubicin—urinary bladder cancer	5.1e-05	0.000742	CcSEcCtD
Topotecan—Pruritus—Gemcitabine—urinary bladder cancer	5.1e-05	0.000742	CcSEcCtD
Topotecan—Nausea—Thiotepa—urinary bladder cancer	5.09e-05	0.00074	CcSEcCtD
Topotecan—Feeling abnormal—Etoposide—urinary bladder cancer	5.07e-05	0.000738	CcSEcCtD
Topotecan—Pneumonia—Doxorubicin—urinary bladder cancer	5.03e-05	0.000732	CcSEcCtD
Topotecan—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.03e-05	0.000732	CcSEcCtD
Topotecan—Pruritus—Fluorouracil—urinary bladder cancer	5.01e-05	0.000729	CcSEcCtD
Topotecan—Infestation NOS—Doxorubicin—urinary bladder cancer	5e-05	0.000728	CcSEcCtD
Topotecan—Infestation—Doxorubicin—urinary bladder cancer	5e-05	0.000728	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	4.97e-05	0.00448	CbGpPWpGaD
Topotecan—Hypersensitivity—Cisplatin—urinary bladder cancer	4.95e-05	0.00072	CcSEcCtD
Topotecan—Diarrhoea—Gemcitabine—urinary bladder cancer	4.93e-05	0.000717	CcSEcCtD
Topotecan—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	4.9e-05	0.000714	CcSEcCtD
Topotecan—Urticaria—Etoposide—urinary bladder cancer	4.89e-05	0.000711	CcSEcCtD
Topotecan—Haemoglobin—Epirubicin—urinary bladder cancer	4.88e-05	0.00071	CcSEcCtD
Topotecan—Stomatitis—Doxorubicin—urinary bladder cancer	4.88e-05	0.00071	CcSEcCtD
Topotecan—Rhinitis—Epirubicin—urinary bladder cancer	4.87e-05	0.000708	CcSEcCtD
Topotecan—Abdominal pain—Etoposide—urinary bladder cancer	4.86e-05	0.000708	CcSEcCtD
Topotecan—Body temperature increased—Etoposide—urinary bladder cancer	4.86e-05	0.000708	CcSEcCtD
Topotecan—Haemorrhage—Epirubicin—urinary bladder cancer	4.85e-05	0.000706	CcSEcCtD
Topotecan—Diarrhoea—Fluorouracil—urinary bladder cancer	4.85e-05	0.000705	CcSEcCtD
Topotecan—Hypoaesthesia—Epirubicin—urinary bladder cancer	4.83e-05	0.000703	CcSEcCtD
Topotecan—Asthenia—Cisplatin—urinary bladder cancer	4.82e-05	0.000701	CcSEcCtD
Topotecan—Pharyngitis—Epirubicin—urinary bladder cancer	4.82e-05	0.000701	CcSEcCtD
Topotecan—Sweating—Doxorubicin—urinary bladder cancer	4.8e-05	0.000698	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—TP53—urinary bladder cancer	4.77e-05	0.0043	CbGpPWpGaD
Topotecan—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	4.73e-05	0.000689	CcSEcCtD
Topotecan—Epistaxis—Doxorubicin—urinary bladder cancer	4.72e-05	0.000687	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—urinary bladder cancer	4.71e-05	0.000685	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—urinary bladder cancer	4.69e-05	0.000682	CcSEcCtD
Topotecan—Dizziness—Fluorouracil—urinary bladder cancer	4.68e-05	0.000682	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—urinary bladder cancer	4.67e-05	0.00068	CcSEcCtD
Topotecan—Chills—Methotrexate—urinary bladder cancer	4.65e-05	0.000677	CcSEcCtD
Topotecan—Diarrhoea—Cisplatin—urinary bladder cancer	4.59e-05	0.000669	CcSEcCtD
Topotecan—Alopecia—Methotrexate—urinary bladder cancer	4.58e-05	0.000667	CcSEcCtD
Topotecan—Vomiting—Gemcitabine—urinary bladder cancer	4.58e-05	0.000667	CcSEcCtD
Topotecan—Rash—Gemcitabine—urinary bladder cancer	4.54e-05	0.000661	CcSEcCtD
Topotecan—Dermatitis—Gemcitabine—urinary bladder cancer	4.54e-05	0.00066	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	4.54e-05	0.00409	CbGpPWpGaD
Topotecan—Hypersensitivity—Etoposide—urinary bladder cancer	4.53e-05	0.00066	CcSEcCtD
Topotecan—Malnutrition—Methotrexate—urinary bladder cancer	4.52e-05	0.000657	CcSEcCtD
Topotecan—Haemoglobin—Doxorubicin—urinary bladder cancer	4.51e-05	0.000657	CcSEcCtD
Topotecan—Headache—Gemcitabine—urinary bladder cancer	4.51e-05	0.000657	CcSEcCtD
Topotecan—Vomiting—Fluorouracil—urinary bladder cancer	4.5e-05	0.000655	CcSEcCtD
Topotecan—Rhinitis—Doxorubicin—urinary bladder cancer	4.5e-05	0.000655	CcSEcCtD
Topotecan—Haemorrhage—Doxorubicin—urinary bladder cancer	4.49e-05	0.000654	CcSEcCtD
Topotecan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	4.47e-05	0.00065	CcSEcCtD
Topotecan—Rash—Fluorouracil—urinary bladder cancer	4.47e-05	0.00065	CcSEcCtD
Topotecan—Dermatitis—Fluorouracil—urinary bladder cancer	4.46e-05	0.000649	CcSEcCtD
Topotecan—Pharyngitis—Doxorubicin—urinary bladder cancer	4.46e-05	0.000649	CcSEcCtD
Topotecan—Headache—Fluorouracil—urinary bladder cancer	4.44e-05	0.000646	CcSEcCtD
Topotecan—Asthenia—Etoposide—urinary bladder cancer	4.41e-05	0.000642	CcSEcCtD
Topotecan—Angiopathy—Epirubicin—urinary bladder cancer	4.4e-05	0.000641	CcSEcCtD
Topotecan—Immune system disorder—Epirubicin—urinary bladder cancer	4.38e-05	0.000638	CcSEcCtD
Topotecan—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.37e-05	0.000637	CcSEcCtD
Topotecan—Back pain—Methotrexate—urinary bladder cancer	4.37e-05	0.000636	CcSEcCtD
Topotecan—Chills—Epirubicin—urinary bladder cancer	4.36e-05	0.000634	CcSEcCtD
Topotecan—Pruritus—Etoposide—urinary bladder cancer	4.35e-05	0.000633	CcSEcCtD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	4.34e-05	0.00392	CbGpPWpGaD
Topotecan—Alopecia—Epirubicin—urinary bladder cancer	4.29e-05	0.000624	CcSEcCtD
Topotecan—Nausea—Gemcitabine—urinary bladder cancer	4.28e-05	0.000623	CcSEcCtD
Topotecan—Vomiting—Cisplatin—urinary bladder cancer	4.27e-05	0.000621	CcSEcCtD
Topotecan—Rash—Cisplatin—urinary bladder cancer	4.23e-05	0.000616	CcSEcCtD
Topotecan—Dermatitis—Cisplatin—urinary bladder cancer	4.23e-05	0.000616	CcSEcCtD
Topotecan—Malnutrition—Epirubicin—urinary bladder cancer	4.23e-05	0.000615	CcSEcCtD
Topotecan—Diarrhoea—Etoposide—urinary bladder cancer	4.21e-05	0.000613	CcSEcCtD
Topotecan—Nausea—Fluorouracil—urinary bladder cancer	4.21e-05	0.000612	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—urinary bladder cancer	4.19e-05	0.00061	CcSEcCtD
Topotecan—Anaemia—Methotrexate—urinary bladder cancer	4.17e-05	0.000607	CcSEcCtD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	4.13e-05	0.00373	CbGpPWpGaD
Topotecan—Back pain—Epirubicin—urinary bladder cancer	4.09e-05	0.000595	CcSEcCtD
Topotecan—Angiopathy—Doxorubicin—urinary bladder cancer	4.07e-05	0.000593	CcSEcCtD
Topotecan—Malaise—Methotrexate—urinary bladder cancer	4.07e-05	0.000592	CcSEcCtD
Topotecan—Dizziness—Etoposide—urinary bladder cancer	4.07e-05	0.000592	CcSEcCtD
Topotecan—Muscle spasms—Epirubicin—urinary bladder cancer	4.06e-05	0.000591	CcSEcCtD
Topotecan—Immune system disorder—Doxorubicin—urinary bladder cancer	4.06e-05	0.00059	CcSEcCtD
Topotecan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.05e-05	0.000589	CcSEcCtD
Topotecan—Leukopenia—Methotrexate—urinary bladder cancer	4.04e-05	0.000588	CcSEcCtD
Topotecan—Chills—Doxorubicin—urinary bladder cancer	4.03e-05	0.000586	CcSEcCtD
Topotecan—Nausea—Cisplatin—urinary bladder cancer	3.99e-05	0.00058	CcSEcCtD
Topotecan—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	3.98e-05	0.00359	CbGpPWpGaD
Topotecan—Alopecia—Doxorubicin—urinary bladder cancer	3.97e-05	0.000578	CcSEcCtD
Topotecan—Cough—Methotrexate—urinary bladder cancer	3.94e-05	0.000573	CcSEcCtD
Topotecan—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	3.92e-05	0.00354	CbGpPWpGaD
Topotecan—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.92e-05	0.00057	CcSEcCtD
Topotecan—Vomiting—Etoposide—urinary bladder cancer	3.91e-05	0.000569	CcSEcCtD
Topotecan—Malnutrition—Doxorubicin—urinary bladder cancer	3.91e-05	0.000569	CcSEcCtD
Topotecan—Anaemia—Epirubicin—urinary bladder cancer	3.91e-05	0.000568	CcSEcCtD
Topotecan—Rash—Etoposide—urinary bladder cancer	3.88e-05	0.000564	CcSEcCtD
Topotecan—Dermatitis—Etoposide—urinary bladder cancer	3.88e-05	0.000564	CcSEcCtD
Topotecan—Headache—Etoposide—urinary bladder cancer	3.85e-05	0.000561	CcSEcCtD
Topotecan—ABCG2—Fluoropyrimidine Activity—TP53—urinary bladder cancer	3.85e-05	0.00347	CbGpPWpGaD
Topotecan—Chest pain—Methotrexate—urinary bladder cancer	3.84e-05	0.000559	CcSEcCtD
Topotecan—Myalgia—Methotrexate—urinary bladder cancer	3.84e-05	0.000559	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—urinary bladder cancer	3.84e-05	0.000559	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.82e-05	0.000556	CcSEcCtD
Topotecan—Malaise—Epirubicin—urinary bladder cancer	3.81e-05	0.000554	CcSEcCtD
Topotecan—Discomfort—Methotrexate—urinary bladder cancer	3.8e-05	0.000553	CcSEcCtD
Topotecan—Leukopenia—Epirubicin—urinary bladder cancer	3.78e-05	0.00055	CcSEcCtD
Topotecan—Back pain—Doxorubicin—urinary bladder cancer	3.78e-05	0.00055	CcSEcCtD
Topotecan—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	3.77e-05	0.0034	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	3.77e-05	0.0034	CbGpPWpGaD
Topotecan—Muscle spasms—Doxorubicin—urinary bladder cancer	3.76e-05	0.000547	CcSEcCtD
Topotecan—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	3.72e-05	0.00336	CbGpPWpGaD
Topotecan—Cough—Epirubicin—urinary bladder cancer	3.69e-05	0.000537	CcSEcCtD
Topotecan—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.69e-05	0.000536	CcSEcCtD
Topotecan—Infection—Methotrexate—urinary bladder cancer	3.66e-05	0.000533	CcSEcCtD
Topotecan—Nausea—Etoposide—urinary bladder cancer	3.65e-05	0.000532	CcSEcCtD
Topotecan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.63e-05	0.000528	CcSEcCtD
Topotecan—Nervous system disorder—Methotrexate—urinary bladder cancer	3.61e-05	0.000526	CcSEcCtD
Topotecan—Anaemia—Doxorubicin—urinary bladder cancer	3.61e-05	0.000526	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.61e-05	0.000525	CcSEcCtD
Topotecan—Myalgia—Epirubicin—urinary bladder cancer	3.6e-05	0.000523	CcSEcCtD
Topotecan—Arthralgia—Epirubicin—urinary bladder cancer	3.6e-05	0.000523	CcSEcCtD
Topotecan—Chest pain—Epirubicin—urinary bladder cancer	3.6e-05	0.000523	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—urinary bladder cancer	3.58e-05	0.000521	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.57e-05	0.00052	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.56e-05	0.000518	CcSEcCtD
Topotecan—Discomfort—Epirubicin—urinary bladder cancer	3.55e-05	0.000517	CcSEcCtD
Topotecan—Malaise—Doxorubicin—urinary bladder cancer	3.53e-05	0.000513	CcSEcCtD
Topotecan—Anorexia—Methotrexate—urinary bladder cancer	3.51e-05	0.000511	CcSEcCtD
Topotecan—Leukopenia—Doxorubicin—urinary bladder cancer	3.5e-05	0.000509	CcSEcCtD
Topotecan—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.45e-05	0.000502	CcSEcCtD
Topotecan—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	3.45e-05	0.00311	CbGpPWpGaD
Topotecan—Infection—Epirubicin—urinary bladder cancer	3.43e-05	0.000499	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	3.42e-05	0.00308	CbGpPWpGaD
Topotecan—Cough—Doxorubicin—urinary bladder cancer	3.41e-05	0.000496	CcSEcCtD
Topotecan—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	3.4e-05	0.00307	CbGpPWpGaD
Topotecan—Nervous system disorder—Epirubicin—urinary bladder cancer	3.38e-05	0.000492	CcSEcCtD
Topotecan—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.38e-05	0.000491	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.36e-05	0.000489	CcSEcCtD
Topotecan—Skin disorder—Epirubicin—urinary bladder cancer	3.35e-05	0.000487	CcSEcCtD
Topotecan—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.33e-05	0.000485	CcSEcCtD
Topotecan—Myalgia—Doxorubicin—urinary bladder cancer	3.33e-05	0.000484	CcSEcCtD
Topotecan—Arthralgia—Doxorubicin—urinary bladder cancer	3.33e-05	0.000484	CcSEcCtD
Topotecan—Chest pain—Doxorubicin—urinary bladder cancer	3.33e-05	0.000484	CcSEcCtD
Topotecan—Paraesthesia—Methotrexate—urinary bladder cancer	3.31e-05	0.000481	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.31e-05	0.000481	CcSEcCtD
Topotecan—Discomfort—Doxorubicin—urinary bladder cancer	3.29e-05	0.000479	CcSEcCtD
Topotecan—Anorexia—Epirubicin—urinary bladder cancer	3.29e-05	0.000478	CcSEcCtD
Topotecan—Dyspnoea—Methotrexate—urinary bladder cancer	3.29e-05	0.000478	CcSEcCtD
Topotecan—Dyspepsia—Methotrexate—urinary bladder cancer	3.24e-05	0.000472	CcSEcCtD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	3.23e-05	0.00292	CbGpPWpGaD
Topotecan—Decreased appetite—Methotrexate—urinary bladder cancer	3.2e-05	0.000466	CcSEcCtD
Topotecan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.19e-05	0.000464	CcSEcCtD
Topotecan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.18e-05	0.000463	CcSEcCtD
Topotecan—Fatigue—Methotrexate—urinary bladder cancer	3.18e-05	0.000462	CcSEcCtD
Topotecan—Infection—Doxorubicin—urinary bladder cancer	3.17e-05	0.000461	CcSEcCtD
Topotecan—Pain—Methotrexate—urinary bladder cancer	3.15e-05	0.000459	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.14e-05	0.000457	CcSEcCtD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	3.14e-05	0.00283	CbGpPWpGaD
Topotecan—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.13e-05	0.000455	CcSEcCtD
Topotecan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.12e-05	0.000455	CcSEcCtD
Topotecan—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	3.1e-05	0.0028	CbGpPWpGaD
Topotecan—Skin disorder—Doxorubicin—urinary bladder cancer	3.1e-05	0.000451	CcSEcCtD
Topotecan—Paraesthesia—Epirubicin—urinary bladder cancer	3.1e-05	0.000451	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	3.09e-05	0.00279	CbGpPWpGaD
Topotecan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	3.08e-05	0.000449	CcSEcCtD
Topotecan—Dyspnoea—Epirubicin—urinary bladder cancer	3.07e-05	0.000447	CcSEcCtD
Topotecan—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	3.06e-05	0.00276	CbGpPWpGaD
Topotecan—Anorexia—Doxorubicin—urinary bladder cancer	3.04e-05	0.000443	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—urinary bladder cancer	3.04e-05	0.000442	CcSEcCtD
Topotecan—Dyspepsia—Epirubicin—urinary bladder cancer	3.04e-05	0.000442	CcSEcCtD
Topotecan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.01e-05	0.000438	CcSEcCtD
Topotecan—Decreased appetite—Epirubicin—urinary bladder cancer	3e-05	0.000436	CcSEcCtD
Topotecan—ABCG2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	2.99e-05	0.0027	CbGpPWpGaD
Topotecan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.98e-05	0.000433	CcSEcCtD
Topotecan—Fatigue—Epirubicin—urinary bladder cancer	2.97e-05	0.000433	CcSEcCtD
Topotecan—Pain—Epirubicin—urinary bladder cancer	2.95e-05	0.000429	CcSEcCtD
Topotecan—Constipation—Epirubicin—urinary bladder cancer	2.95e-05	0.000429	CcSEcCtD
Topotecan—Urticaria—Methotrexate—urinary bladder cancer	2.93e-05	0.000426	CcSEcCtD
Topotecan—Body temperature increased—Methotrexate—urinary bladder cancer	2.91e-05	0.000424	CcSEcCtD
Topotecan—Abdominal pain—Methotrexate—urinary bladder cancer	2.91e-05	0.000424	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.91e-05	0.000423	CcSEcCtD
Topotecan—Paraesthesia—Doxorubicin—urinary bladder cancer	2.87e-05	0.000417	CcSEcCtD
Topotecan—Dyspnoea—Doxorubicin—urinary bladder cancer	2.84e-05	0.000414	CcSEcCtD
Topotecan—Feeling abnormal—Epirubicin—urinary bladder cancer	2.84e-05	0.000414	CcSEcCtD
Topotecan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.82e-05	0.00041	CcSEcCtD
Topotecan—Dyspepsia—Doxorubicin—urinary bladder cancer	2.81e-05	0.000409	CcSEcCtD
Topotecan—Decreased appetite—Doxorubicin—urinary bladder cancer	2.77e-05	0.000404	CcSEcCtD
Topotecan—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	2.77e-05	0.0025	CbGpPWpGaD
Topotecan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.75e-05	0.000401	CcSEcCtD
Topotecan—Fatigue—Doxorubicin—urinary bladder cancer	2.75e-05	0.0004	CcSEcCtD
Topotecan—Urticaria—Epirubicin—urinary bladder cancer	2.74e-05	0.000399	CcSEcCtD
Topotecan—Pain—Doxorubicin—urinary bladder cancer	2.73e-05	0.000397	CcSEcCtD
Topotecan—Constipation—Doxorubicin—urinary bladder cancer	2.73e-05	0.000397	CcSEcCtD
Topotecan—Abdominal pain—Epirubicin—urinary bladder cancer	2.73e-05	0.000397	CcSEcCtD
Topotecan—Body temperature increased—Epirubicin—urinary bladder cancer	2.73e-05	0.000397	CcSEcCtD
Topotecan—Hypersensitivity—Methotrexate—urinary bladder cancer	2.72e-05	0.000395	CcSEcCtD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	2.67e-05	0.00241	CbGpPWpGaD
Topotecan—Asthenia—Methotrexate—urinary bladder cancer	2.64e-05	0.000385	CcSEcCtD
Topotecan—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.63e-05	0.000383	CcSEcCtD
Topotecan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.61e-05	0.00038	CcSEcCtD
Topotecan—Pruritus—Methotrexate—urinary bladder cancer	2.61e-05	0.000379	CcSEcCtD
Topotecan—Hypersensitivity—Epirubicin—urinary bladder cancer	2.54e-05	0.00037	CcSEcCtD
Topotecan—Urticaria—Doxorubicin—urinary bladder cancer	2.53e-05	0.000369	CcSEcCtD
Topotecan—Body temperature increased—Doxorubicin—urinary bladder cancer	2.52e-05	0.000367	CcSEcCtD
Topotecan—Abdominal pain—Doxorubicin—urinary bladder cancer	2.52e-05	0.000367	CcSEcCtD
Topotecan—Diarrhoea—Methotrexate—urinary bladder cancer	2.52e-05	0.000367	CcSEcCtD
Topotecan—Asthenia—Epirubicin—urinary bladder cancer	2.47e-05	0.00036	CcSEcCtD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	2.46e-05	0.00222	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	2.45e-05	0.00221	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	2.45e-05	0.00221	CbGpPWpGaD
Topotecan—Pruritus—Epirubicin—urinary bladder cancer	2.44e-05	0.000355	CcSEcCtD
Topotecan—Dizziness—Methotrexate—urinary bladder cancer	2.44e-05	0.000355	CcSEcCtD
Topotecan—ABCG2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.44e-05	0.0022	CbGpPWpGaD
Topotecan—Diarrhoea—Epirubicin—urinary bladder cancer	2.36e-05	0.000343	CcSEcCtD
Topotecan—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.35e-05	0.000342	CcSEcCtD
Topotecan—Vomiting—Methotrexate—urinary bladder cancer	2.34e-05	0.000341	CcSEcCtD
Topotecan—Rash—Methotrexate—urinary bladder cancer	2.32e-05	0.000338	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—urinary bladder cancer	2.32e-05	0.000338	CcSEcCtD
Topotecan—Headache—Methotrexate—urinary bladder cancer	2.31e-05	0.000336	CcSEcCtD
Topotecan—Asthenia—Doxorubicin—urinary bladder cancer	2.29e-05	0.000333	CcSEcCtD
Topotecan—Dizziness—Epirubicin—urinary bladder cancer	2.28e-05	0.000332	CcSEcCtD
Topotecan—Pruritus—Doxorubicin—urinary bladder cancer	2.26e-05	0.000328	CcSEcCtD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	2.23e-05	0.00202	CbGpPWpGaD
Topotecan—Vomiting—Epirubicin—urinary bladder cancer	2.19e-05	0.000319	CcSEcCtD
Topotecan—Nausea—Methotrexate—urinary bladder cancer	2.19e-05	0.000319	CcSEcCtD
Topotecan—Diarrhoea—Doxorubicin—urinary bladder cancer	2.18e-05	0.000318	CcSEcCtD
Topotecan—Rash—Epirubicin—urinary bladder cancer	2.17e-05	0.000316	CcSEcCtD
Topotecan—Dermatitis—Epirubicin—urinary bladder cancer	2.17e-05	0.000316	CcSEcCtD
Topotecan—Headache—Epirubicin—urinary bladder cancer	2.16e-05	0.000314	CcSEcCtD
Topotecan—Dizziness—Doxorubicin—urinary bladder cancer	2.11e-05	0.000307	CcSEcCtD
Topotecan—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	2.07e-05	0.00186	CbGpPWpGaD
Topotecan—Nausea—Epirubicin—urinary bladder cancer	2.05e-05	0.000298	CcSEcCtD
Topotecan—ABCG2—Metabolism—GSTZ1—urinary bladder cancer	2.04e-05	0.00184	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	2.04e-05	0.00184	CbGpPWpGaD
Topotecan—Vomiting—Doxorubicin—urinary bladder cancer	2.03e-05	0.000295	CcSEcCtD
Topotecan—Rash—Doxorubicin—urinary bladder cancer	2.01e-05	0.000293	CcSEcCtD
Topotecan—Dermatitis—Doxorubicin—urinary bladder cancer	2.01e-05	0.000292	CcSEcCtD
Topotecan—Headache—Doxorubicin—urinary bladder cancer	2e-05	0.000291	CcSEcCtD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	1.97e-05	0.00178	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTO2—urinary bladder cancer	1.94e-05	0.00175	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NAT1—urinary bladder cancer	1.94e-05	0.00175	CbGpPWpGaD
Topotecan—Nausea—Doxorubicin—urinary bladder cancer	1.9e-05	0.000276	CcSEcCtD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	1.85e-05	0.00167	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—UGT2B7—urinary bladder cancer	1.77e-05	0.0016	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	1.69e-05	0.00152	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	1.67e-05	0.00151	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	1.65e-05	0.00149	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.65e-05	0.00148	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	1.62e-05	0.00146	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	1.61e-05	0.00146	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	1.6e-05	0.00145	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	1.59e-05	0.00144	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	1.57e-05	0.00142	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	1.54e-05	0.00139	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	1.51e-05	0.00136	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PRSS3—urinary bladder cancer	1.47e-05	0.00132	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	1.37e-05	0.00123	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	1.32e-05	0.00119	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	1.21e-05	0.00109	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	1.2e-05	0.00108	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	1.2e-05	0.00108	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	1.17e-05	0.00106	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—TYMP—urinary bladder cancer	1.17e-05	0.00106	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.11e-05	0.001	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	1.1e-05	0.000996	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.1e-05	0.000988	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NAT2—urinary bladder cancer	1.06e-05	0.000957	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.05e-05	0.000946	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTO2—urinary bladder cancer	1.05e-05	0.000944	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NAT1—urinary bladder cancer	1.05e-05	0.000944	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.04e-05	0.000934	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.02e-05	0.000921	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.01e-05	0.000908	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	9.57e-06	0.000864	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—RRM2—urinary bladder cancer	9.16e-06	0.000826	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.9e-06	0.000803	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	8.78e-06	0.000792	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	8.62e-06	0.000778	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	8.59e-06	0.000775	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ENO2—urinary bladder cancer	8.48e-06	0.000765	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—HPGDS—urinary bladder cancer	8.48e-06	0.000765	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTT1—urinary bladder cancer	8.22e-06	0.000742	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	8.14e-06	0.000734	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PRSS3—urinary bladder cancer	7.93e-06	0.000716	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	7.76e-06	0.0007	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.7e-06	0.000695	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	7.5e-06	0.000677	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	7.49e-06	0.000676	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	7.14e-06	0.000644	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	6.94e-06	0.000627	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NQO1—urinary bladder cancer	6.83e-06	0.000617	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	6.8e-06	0.000614	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	6.45e-06	0.000582	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NAT1—urinary bladder cancer	6.45e-06	0.000582	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—TYMP—urinary bladder cancer	6.34e-06	0.000572	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	6.22e-06	0.000561	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	6.09e-06	0.000549	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	5.9e-06	0.000532	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	5.8e-06	0.000523	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	5.75e-06	0.000519	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NAT2—urinary bladder cancer	5.73e-06	0.000517	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTP1—urinary bladder cancer	5.7e-06	0.000514	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	5.31e-06	0.000479	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—TYMS—urinary bladder cancer	5.3e-06	0.000478	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTM1—urinary bladder cancer	5.24e-06	0.000473	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NCOR1—urinary bladder cancer	5.24e-06	0.000473	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	5.11e-06	0.000461	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GPX1—urinary bladder cancer	5.02e-06	0.000453	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.01e-06	0.000452	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—RRM2—urinary bladder cancer	4.95e-06	0.000447	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ERCC2—urinary bladder cancer	4.92e-06	0.000444	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.89e-06	0.000441	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—MTHFR—urinary bladder cancer	4.63e-06	0.000418	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ENO2—urinary bladder cancer	4.58e-06	0.000414	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—HPGDS—urinary bladder cancer	4.58e-06	0.000414	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTT1—urinary bladder cancer	4.45e-06	0.000401	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.16e-06	0.000376	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.91e-06	0.000353	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PPARG—urinary bladder cancer	3.75e-06	0.000339	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NQO1—urinary bladder cancer	3.7e-06	0.000333	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CREBBP—urinary bladder cancer	3.61e-06	0.000325	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.53e-06	0.000319	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTP1—urinary bladder cancer	3.08e-06	0.000278	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.05e-06	0.000275	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTGS2—urinary bladder cancer	2.95e-06	0.000266	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.87e-06	0.000259	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.83e-06	0.000256	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.83e-06	0.000256	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.82e-06	0.000255	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.82e-06	0.000255	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.74e-06	0.000247	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GPX1—urinary bladder cancer	2.71e-06	0.000245	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ERCC2—urinary bladder cancer	2.66e-06	0.00024	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTEN—urinary bladder cancer	2.58e-06	0.000232	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—MTHFR—urinary bladder cancer	2.5e-06	0.000226	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—EP300—urinary bladder cancer	2.46e-06	0.000222	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.28e-06	0.000205	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PPARG—urinary bladder cancer	2.03e-06	0.000183	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.95e-06	0.000176	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.9e-06	0.000171	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.77e-06	0.000159	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.74e-06	0.000157	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.74e-06	0.000157	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.67e-06	0.000151	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.64e-06	0.000148	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.6e-06	0.000144	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.54e-06	0.000139	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.39e-06	0.000126	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—EP300—urinary bladder cancer	1.33e-06	0.00012	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.25e-06	0.000113	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.2e-06	0.000108	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	9.84e-07	8.88e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTEN—urinary bladder cancer	8.58e-07	7.74e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—EP300—urinary bladder cancer	8.18e-07	7.38e-05	CbGpPWpGaD
